Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Praxis Precision Medicines, Inc. Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress September 26, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines to Participate in Upcoming Investor Conferences September 05, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations September 04, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers IONS PRAX Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine September 03, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024 September 02, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results August 13, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024 August 05, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 04, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines to Participate in Upcoming Investor Conferences May 17, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results May 13, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024 May 10, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 03, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting April 12, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines to Participate in Upcoming April Conferences April 05, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 02, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering March 28, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines, Inc. Announces Proposed Public Offering March 27, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients March 26, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines to Host PRAX-628 Program Update March 25, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results March 05, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference March 01, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 02, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering January 11, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines, Inc. Announces Proposed Public Offering January 10, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio January 08, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers IONS PRAX Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China January 05, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings November 28, 2023 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference November 21, 2023 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies November 16, 2023 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers IONS PRAX Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results November 07, 2023 From Praxis Precision Medicines, Inc. Via GlobeNewswire Tickers PRAX Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.